Quantcast

Colorectal Cancer Therapeutics: Global Markets to 2023 with Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi at the Forefront

Global Markets to 2023 with Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi at the Forefront

Read more

First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute

STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient

Read more

Immunicium to treat cancer patients with its lead in-development-product, ILIAD

Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.

Read more

ValiRX finds support for future studies of VAL401 as a cancer treatment

ValiRx’s published study of VAL401, a single dose in an open-label trial of late-stage cancer patients, provide support for future studies of VAL401 as a cancer treatment, as the Cmaxdemonstrates sufficient exposure to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports the use of the safety and tolerability data from conventional risperidone during future clinical trials.

Read more